Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States

Paul E Sax, Juliana L Meyers, Michael Mugavero, Keith L Davis, Paul E Sax, Juliana L Meyers, Michael Mugavero, Keith L Davis

Abstract

Purpose: A lower daily pill burden may improve adherence to antiretroviral treatment (ART) and clinical outcomes in patients with human immunodeficiency virus (HIV). This study assessed differences in adherence using the number of pills taken per day, and evaluated how adherence correlated with hospitalization.

Methodology: Commercially insured patients in the LifeLink database with an HIV diagnosis (International Classification of Diseases, 9th Revision, Clinical Modification code 042.xx) between 6/1/2006 and 12/31/2008 and receipt of a complete ART regimen were selected for inclusion. Patients were grouped according to their daily pill count and remained on ART for at least 60 days. Outcomes included adherence and rates of hospitalization. Adherence was measured as the proportion of days between the start and end of the regimen in which the patient maintained supply of all initiated ART components. Logistic regressions assessed the relationship between pills per day, adherence, and hospitalization, controlling for demographics, comorbidities, and ART-naïve (vs. experienced) status.

Results: 7,073 patients met the study inclusion criteria, and 33.4%, 5.8%, and 60.8% received an ART regimen comprising one, two, or three or more pills per day, respectively. Regression analysis showed patients receiving a single pill per day were significantly more likely to reach a 95% adherence threshold versus patients receiving three or more pills per day (odds ratio [OR] = 1.59; P<0.001). Regardless of the number of pills received per day, patients were over 40% less likely to have a hospitalization if they were adherent to therapy (OR = 0.57; P<0.001). Patients receiving a single pill per day were 24% less likely to have a hospitalization versus patients receiving three or more pills per day (OR = 0.76; P = 0.003).

Conclusions: ART consisting of a single pill per day was associated with significantly better adherence and lower risk of hospitalization in patients with HIV compared to patients receiving three or more pills per day.

Conflict of interest statement

Competing Interests: This study was funded by Gilead Sciences.

Figures

Figure 1. Sample Selection Flow Chart.
Figure 1. Sample Selection Flow Chart.
Figure 2. Frequency of Hospitalizations, by Cohort…
Figure 2. Frequency of Hospitalizations, by Cohorta.
Figure 3. Adjusted Rate of Hospitalization, by…
Figure 3. Adjusted Rate of Hospitalization, by Cohort.

References

    1. Fielden SJ, Rusch ML, Yip B, Wood E, Shannon K, et al. Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naïve patients started on HAART. J Int Assoc Physicians AIDS Care. 2008;7:238–244.
    1. Kitahata MM, Reed SD, Dillingham PW, Van Rompaey SE, Young AA, et al. Pharmacy-based assessment of adherence to HAART predicts virological and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004;15:803–810.
    1. Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350×109 cells/L. Ann Intern Med. 2003;139:810–816.
    1. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, et al. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–1183.
    1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. 2009. Available: . Accessed 2011 Feb 4.
    1. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, et al. Recommendations of the IAS-USA Panel. JAMA. 2010;304:321–333.
    1. DeJesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, et al. Simplification of antiretroviral therapy to a single tablet regimen consisting of efavirenz, emtricitabine and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51:163–174.
    1. Hodder SL, Mounzer K, DeJesus E, Ebrahimi R, Grimm K, et al. Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single tablet regimen of efavirenz, emtricitabine and tenofovir DF. AIDS Patient Care STDs. 2010;24:115–125.
    1. Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115–125.
    1. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24:2835–2840.
    1. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–383.
    1. Andrade SE, Kristijan KH, Frech F, Chan K. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–574.
    1. Legorreta A, Yu A, Chernicoff H, Gilmore A, Jordan J, et al. Adherence to combined lamivudine+zidovudine versus individual components: a community-based retrospective Medicaid claims analysis. AIDS Care. 2005;17:938–948.
    1. Parienti J-J, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48:484–488.
    1. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report an electronic monitoring. Clin Infect Dis. 2001;33:1417–1423.
    1. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–366.
    1. Andrews L, Friedland G. Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy. Infect Dis Clin North Am. 2000;14:901–928.
    1. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–941.
    1. Cohen CJ, Colson AE, Shebie-Hall AG, McLaughlin KA, Morse GD. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials. 2007;8:19–23.
    1. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011;25:F7–F12.
    1. Cohen C, Molina J-M, Cahn P, Clotet B, Supparatpinyo K, et al. Pooled 48 week efficacy and safety results from ECHO and THRIVE, two double-blind, randomized, phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients. 2010. Abstract presented at the World AIDS Conference; Vienna, Austria. 18–23 July. Abstract No. THLBB206.
    1. Bangsberg DR, Ragland K, Monk A, Deeks SG. A one-pill, once-daily, fixed-dose combination (FDC) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (EFV/FTC/TDF) regimen is associated with higher unannounced pill count adherence than non-one pill, once-daily. 2010. Abstract presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA. 16–19 February. Abstract No. 510.
    1. Fielden SJ, Rusch ML, Yip B, Wood E, Shannon K, et al. Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naïve patients started on HAART. J Int Assoc Physicians AIDS Care. 2008;7:238–244.
    1. Juday T, Gupta S, Grimm K, Wagner S, Kim E. Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials. 2011;12:71–78.
    1. McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011;52:493–506.
    1. Daar ES, Tierney C, Fischi MA, Sax PE, Mollan K, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445–456.
    1. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–2106.
    1. Hellinger FJ, Encinosa WE. The cost and incidence of prescribing errors among privately insured HIV patients. Pharmacoeconomics. 2010;28:23–34.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren